Meeting
2019 Gastrointestinal Cancers Symposium
Plasma hyaluronan is a predictive marker for pegvorhyaluronidase alfa (PEGPH20; PVHA) response in a phase II study of pancreatic ductal adenocarcinoma (PDAC).
Authors
Darin Taverna
Halozyme Therapeutics, Inc., San Diego, CA
Darin Taverna , Marie Printz , Michael J. LaBarre , Rose E. Sekulovich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 404)
DOI
10.1200/JCO.2019.37.4_suppl.404
Abstract #
404
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Extracellular matrix (ECM) circulating peptide biomarkers as potential predictors of survival in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (mPDA) receiving pegvorhyaluronidase alfa (PEGPH20), nab-paclitaxel (A), and gemcitabine (G).
First Author: Song Wang
Poster
2016 ASCO Annual Meeting
Final analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay.
First Author: Andrea J. Bullock
Poster
2016 Gastrointestinal Cancers Symposium
Interim results of a randomized phase II study of PEGPH20 added to nab‑paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.
First Author: Sunil R. Hingorani
Poster
2022 ASCO Annual Meeting
Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial.
First Author: Thomas Jens Ettrich